Ribera, JordiGranada, IsabelMorgades, MireiaGonzález, TeresaCiudad, JuanaSuch, EsperanzaCalasanz, María-JoséMercadal, SantiagoColl, RosaGonzález-Campos, JoséTormo, MarGarcía-Cadenas, IreneGil, CristinaCervera, MartaBarba, PereCosta, DolorsAyala, RosaBermúdez, AranchaOrfao, AlbertoRibera, Josep-MariaPrograma para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH)2023-02-092023-02-092021-09-21http://hdl.handle.net/10668/18532The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent and adult patients with t(1;19)(q23;p13) enrolled in paediatric-inspired trials. The patients with TCF3-PBX1 showed similar MRD clearance and did not have different survival compared with other B-cell precursor ALL patients. However, patients with TCF3-PBX1 had a significantly higher cumulative incidence of relapse, especially among patients aged ≥35 years carrying additional cytogenetic alterations. These patients might benefit from additional/intensified therapy (e.g. immunotherapy in first complete remission with or without subsequent haematopoietic stem cell transplantation).enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/acute lymphoblastic leukaemiaadultscytogenetic alterationsprognosist(1;19)(q23;p13)/TCF3-PBX1AdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsChromosome BandingChromosomes, Human, Pair 1Chromosomes, Human, Pair 19Disease ManagementFemaleHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingNeoplasm, ResidualOncogene Proteins, FusionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrognosisRemission InductionTranslocation, GeneticTreatment OutcomeYoung AdultPrognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.research article34549416open access10.1111/bjh.178441365-2141https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.17844